Viz.ai and Alnylam Push AI Into Rare Cardiac Disease Detection
A new partnership between Viz.ai and Alnylam Pharmaceuticals aims to improve detection of cardiac amyloidosis, a frequently underdiagnosed condition. The collaboration shows how AI is being used not only to speed common workflows, but to surface missed patients in high-value specialty disease areas.
The partnership between Viz.ai and Alnylam Pharmaceuticals, reported by MobiHealthNews, highlights one of the more strategically important applications of clinical AI: finding patients who are present in the system but not yet identified. Cardiac amyloidosis is an especially relevant target because it is often underrecognized, diagnostically delayed and increasingly actionable as therapies improve.
This kind of collaboration sits at the intersection of digital health, specialty pharma and clinical pathway redesign. For a company like Alnylam, better identification expands the diagnosable population and may shorten time to treatment. For a platform like Viz.ai, disease detection moves the company beyond acute-event workflow tools and deeper into longitudinal case finding, where the commercial and clinical upside can be substantial.
The broader implication is that AI-enabled screening is becoming a go-to strategy for diseases with high underdiagnosis rates. Rather than replacing specialists, these tools aim to increase the probability that the right patient reaches the right specialist sooner. That can be particularly valuable in rare and complex conditions where pattern recognition exists in data, but frontline clinicians may not see enough cases to detect it reliably.
Still, success depends on more than algorithmic performance. Health systems need pathways for confirmation, referral and treatment access once a patient is flagged. Without that downstream infrastructure, detection AI risks creating alerts without impact. The strongest programs will be those that connect identification directly to care orchestration.